Poehling Capital Management’s Biogen BIIB Stock Holding History

Poehling Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$210K	Buy	+1,144	New	+$211K	0.04%	145

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Poehling Capital Management's BIIB Position: Q1 2026 in Review

Poehling Capital Management opened a new position in Biogen (BIIB) in Q1 2026: 1,144 shares worth $210K. The stake represents 0.04% of the portfolio and ranks #145 among its holdings.

1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Poehling Capital Management held 1,144 shares of Biogen worth $210K as of Q1 2026.
Biogen was a new Poehling Capital Management position in Q1 2026.
Biogen made up 0.04% of Poehling Capital Management's portfolio in Q1 2026, its #145 holding.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Poehling Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.